NASDAQ:ARWR Arrowhead Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $39.99 +0.83 (+2.12%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$38.88▼$40.7150-Day Range$27.79▼$43.0552-Week Range$26.81▼$84.83Volume1.01 million shsAverage Volume800,802 shsMarket Capitalization$4.23 billionP/E RatioN/ADividend YieldN/APrice Target$73.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Arrowhead Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside82.5% Upside$73.00 Price TargetShort InterestBearish6.10% of Float Sold ShortDividend StrengthN/ASustainability-2.57Upright™ Environmental ScoreNews Sentiment0.28Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.03) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.95 out of 5 starsMedical Sector567th out of 1,426 stocksPharmaceutical Preparations Industry271st out of 682 stocks 3.4 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $73.00, Arrowhead Pharmaceuticals has a forecasted upside of 82.5% from its current price of $39.99.Amount of Analyst CoverageArrowhead Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.10% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 11.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 44.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "RNA interference medication for cancer", "Cardiovascular siRNA medication", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.57. Previous Next 2.4 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arrowhead Pharmaceuticals this week, compared to 1 article on an average week.Search Interest10 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions64.62% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($1.03) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -36.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -36.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 10.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Arrowhead Pharmaceuticals (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.Read More ARWR Stock News HeadlinesJuly 6, 2022 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 1, 2022 | seekingalpha.comMy 26 Stock $336k Portfolio Outperforms The Market In Horrendous June Because Of This Key TradeJuly 1, 2022 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 3.4%June 30, 2022 | nasdaq.com5 Top Biotech Stocks To Watch In July 2022June 28, 2022 | seekingalpha.comArrowhead Pharma: We Can Afford To Wait For More ProofJune 27, 2022 | bizjournals.comMilliporeSigma opens $65 million facility in VeronaJune 27, 2022 | finance.yahoo.comDrug reduces mutant protein that can lead to fibrosis in rare genetic liver diseaseJune 16, 2022 | finance.yahoo.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Is In A Strong Position To Grow Its BusinessJune 16, 2022 | nasdaq.comRelative Strength Alert For Arrowhead PharmaceuticalsMay 10, 2022 | investing.comArrowhead Pharmaceuticals Inc. Tops Q2 EPS by 44cMay 9, 2022 | bizjournals.comArrowhead breaks ground on up to $250M Verona project, will receive incentivesMay 2, 2022 | finance.yahoo.comArrowhead Pharmaceuticals to Participate in Upcoming May 2022 ConferencesMay 2, 2022 | apnews.comArrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of DirectorsApril 26, 2022 | seekingalpha.comArrowhead begins dosing in phase 2 trial of ARO-ANG3 to treat cholesterol disorderApril 26, 2022 | finance.yahoo.comArrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial HypercholesterolemiaApril 14, 2022 | seekingalpha.comArrowhead Pharma: Know Pros' Calcs For Coming Stock PricesMarch 24, 2022 | seekingalpha.comArrowhead Pharmaceuticals asks regulators to begin early-stage asthma trialFebruary 24, 2022 | finance.yahoo.comArrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed DyslipidemiaFebruary 18, 2022 | finance.yahoo.comArrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated DiseasesFebruary 17, 2022 | finance.yahoo.comArrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022January 24, 2022 | finance.yahoo.comArrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKlineJanuary 20, 2022 | benzinga.comGoldman Sachs Upgrades Arrowhead Pharmaceuticals to BuyJanuary 12, 2022 | seekingalpha.comArrowhead Pharma initiates late-stage ARO-APOC3 study for familial chylomicronemia syndromeJanuary 12, 2022 | finance.yahoo.comArrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia SyndromeDecember 23, 2021 | bizjournals.comDrug company buys land for up to $250 million, 250-job Verona campusSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees329Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/06/2022Next Earnings (Estimated)8/04/2022Fiscal Year End9/30/2022Price Target and Rating Average Stock Price Forecast$73.00 High Stock Price Forecast$110.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside+82.5%Consensus RatingModerate Buy Rating Score (0-4)2.83333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-140,850,000.00 Net Margins-42.44% Pretax Margin-42.44% Return on Equity-26.77% Return on Assets-16.05% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual Sales$138.29 million Price / Sales30.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.92 per share Price / Book10.20Miscellaneous Outstanding Shares105,736,000Free Float102,352,000Market Cap$4.23 billion OptionableOptionable Beta1.36 Arrowhead Pharmaceuticals Frequently Asked Questions Should I buy or sell Arrowhead Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock. View analyst ratings for Arrowhead Pharmaceuticals or view top-rated stocks. What is Arrowhead Pharmaceuticals' stock price forecast for 2022? 6 Wall Street research analysts have issued 1 year price objectives for Arrowhead Pharmaceuticals' shares. Their ARWR stock forecasts range from $36.00 to $110.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $73.00 in the next year. This suggests a possible upside of 82.5% from the stock's current price. View analysts' price targets for Arrowhead Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Arrowhead Pharmaceuticals' stock price performed in 2022? Arrowhead Pharmaceuticals' stock was trading at $66.30 on January 1st, 2022. Since then, ARWR shares have decreased by 39.7% and is now trading at $39.99. View the best growth stocks for 2022 here. When is Arrowhead Pharmaceuticals' next earnings date? Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Arrowhead Pharmaceuticals. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02. The biotechnology company earned $151.80 million during the quarter, compared to the consensus estimate of $122.15 million. Arrowhead Pharmaceuticals had a negative net margin of 42.44% and a negative trailing twelve-month return on equity of 26.77%. The business's quarterly revenue was up 362.8% compared to the same quarter last year. During the same period last year, the business posted ($0.26) EPS. View Arrowhead Pharmaceuticals' earnings history. Who are Arrowhead Pharmaceuticals' key executives? Arrowhead Pharmaceuticals' management team includes the following people: Dr. Christopher R. Anzalone Ph.D., CEO, Pres & Director (Age 53, Pay $1.68M)Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 56, Pay $729.77k) (LinkedIn Profile)Mr. Patrick O'Brien, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 58, Pay $733.13k)Dr. James C. Hamilton M.D., MBA, Sr. VP of Discovery & Translational Medicine (Age 43, Pay $673.45k)Dr. Javier San Martin M.D., Chief Medical Officer (Age 57, Pay $658.48k)Dr. Mark M. Davis Ph.D., Founder and Founder & Director of Insert Therapeutics Inc & CalandoMs. Jane Davidson, Head of HR & Admin., VP and Corp. Sec.Dr. Vincent Anzalone CFA, Head of Investor Relations & VPMr. Howard Lovy, Director of CommunicationsDr. Mark Seefeld, Head of Toxicology & VP (Age 68) Who are some of Arrowhead Pharmaceuticals' key competitors? Some companies that are related to Arrowhead Pharmaceuticals include Shiseido (SSDOY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Viatris (VTRS), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Legend Biotech (LEGN), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS) and Maravai LifeSciences (MRVI). View all of ARWR's competitors. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD). What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $39.99. How much money does Arrowhead Pharmaceuticals make? Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $4.23 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140,850,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. How many employees does Arrowhead Pharmaceuticals have? Arrowhead Pharmaceuticals employs 329 workers across the globe. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401. This page (NASDAQ:ARWR) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
